Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of the company's management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon

You may also be interested in...



Final Assault: Daiichi Sankyo Threatens Legal Action Against Former Ranbaxy Shareholders For Concealing Information

Breaking its silence after four years, Daiichi Sankyo hinted for the first time that it would pursue legal remedies against former shareholders of Ranbaxy, which the Japanese company bought in 2008 to expand into emerging markets and the generics drug space.

Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?

MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites

Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?

MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites

Related Content

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel